Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers SquibbGlobeNewsWire • 11/09/20
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219GlobeNewsWire • 10/27/20
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual ConferenceGlobeNewsWire • 10/16/20
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer PatientsGlobeNewsWire • 09/08/20
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219GlobeNewsWire • 09/04/20
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial ResultsGlobeNewsWire • 08/11/20
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/03/20
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer PatientsGlobeNewsWire • 07/09/20
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 AntibodyGlobeNewsWire • 07/08/20
Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer PatientsGlobeNewsWire • 05/22/20
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting IIGlobeNewsWire • 05/19/20
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific ProgramGlobeNewsWire • 05/14/20
Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of WarrantsGlobeNewsWire • 04/20/20
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue ForecastGlobeNewsWire • 03/12/20